Page last updated: 2024-11-12
notoamide b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
notoamide B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 16127923 |
CHEMBL ID | 2042022 |
MeSH ID | M0510811 |
Synonyms (6)
Synonym |
---|
(-)-notoamide b |
CHEMBL2042022 |
notoamide b |
(1's,3r,7's,9's)-7,7,10',10'-tetramethylspiro[1h-pyrano[2,3-g]indole-3,11'-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,2',14'-trione |
937791-52-1 |
DTXSID801046203 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (14)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID667073 | Antifungal activity against Candida albicans DAY185 assessed as inhibition of biofilm formation after 48 hrs by XTT assay | 2012 | Journal of natural products, Apr-27, Volume: 75, Issue:4 | Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans. |
AID735803 | Cytotoxicity against human HL60 cells assessed as inhibition of cell viability by MTT assay | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID1634821 | Activation of Escherichia coli BLR (DE3) ClpP using bovine milk FITC-beta casein as substrate assessed as change in relative fluorescent units at 50 uM preincubated for 15 mins followed by substrate addition measured every 30 mins for 6 hrs by fluorescenc | 2016 | Journal of natural products, Apr-22, Volume: 79, Issue:4 | Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P. |
AID735808 | Antibacterial activity against Vibrio anguillarum ATCC 19019 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID735809 | Antibacterial activity against Escherichia coli ATCC 25922 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID735813 | Antibacterial activity against Bacillus cereus ACCC 11077 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID735811 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID735807 | Antibacterial activity against Vibrio parahaemolyticus ATCC 17802 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID735806 | Antibacterial activity against Pseudomonas putida ATCC 17848 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID1465315 | Inhibition of RANKL-induced formation of multinuclear osteoclasts in mouse RAW264 cells at 10 ug/ml after 4 days by p-NPP substrate based absorbance method | 2017 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22 | Enantioselective inhibitory abilities of enantiomers of notoamides against RANKL-induced formation of multinuclear osteoclasts. |
AID735810 | Antibacterial activity against Staphylococcus aureus ATCC 27154 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID667072 | Antifungal activity against Candida albicans DAY185 assessed as lowest compound concentration causing =>80% reduction in cell viability after 48 hrs by XTT assay | 2012 | Journal of natural products, Apr-27, Volume: 75, Issue:4 | Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans. |
AID735812 | Antibacterial activity against Micrococcus tetragenus ATCC 13623 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
AID735804 | Cytotoxicity against human K562 cells assessed as inhibition of cell viability by MTT assay | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 10 (71.43) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.12) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.14%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (92.86%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |